Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday. They currently have a $9.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 13.21% from the stock’s previous close.
According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “
TRIL has been the topic of several other research reports. ValuEngine raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Trillium Therapeutics in a research note on Thursday, December 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Trillium Therapeutics has an average rating of “Hold” and a consensus target price of $12.33.
Institutional investors and hedge funds have recently made changes to their positions in the business. AWM Investment Company Inc. acquired a new position in shares of Trillium Therapeutics during the 2nd quarter valued at about $4,415,000. Janus Henderson Group PLC acquired a new position in shares of Trillium Therapeutics during the 2nd quarter valued at about $2,395,000. Tekla Capital Management LLC acquired a new position in shares of Trillium Therapeutics during the 2nd quarter valued at about $1,980,000. Sectoral Asset Management Inc boosted its position in shares of Trillium Therapeutics by 27.8% during the 3rd quarter. Sectoral Asset Management Inc now owns 234,248 shares of the biotechnology company’s stock valued at $1,206,000 after acquiring an additional 50,976 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its position in shares of Trillium Therapeutics by 88.9% during the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 68,970 shares during the last quarter. 47.18% of the stock is currently owned by institutional investors.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company?s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.